BIOA — BioAge Labs, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1709941 ·
Last close
$5.10
Market Cap
$234.35M
52W High
$25.95
52W Low
$4.81
ADV30
727,499
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 298,000 | — | -37,411,000 | -33,504,000 | 367,648,000 | 52,666,000 | 21,202,000 |
| Jun 2026 | 2,451,000 | — | -29,333,000 | -26,097,000 | 396,929,000 | 73,964,000 | 22,016,000 |
| Mar 2026 | 2,772,000 | — | -25,375,000 | -22,253,000 | 397,654,000 | 241,777,000 | 18,533,000 |
| Dec 2025 | 3,078,000 | — | -28,423,000 | -25,943,000 | 294,889,000 | 188,888,000 | 22,838,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-87,601,000
Investing CF
$-212,854,000
Financing CF
$154,150,000
CapEx
$-488,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.26
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-381,766,000
Inventory
—
Receivables
$625,000
ST Investments
$244,781,000
EBIT TTM
$-94,183,000
Pretax Income TTM
$-94,464,000
Interest Exp TTM
$281,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$8,599,000
EBITDA
$-120,260,000
Free Cash Flow
$-71,778,248
Enterprise Value
$-35,488,560
Total Cash
$283,636,992
Total Debt
$2,730,000
Shares Out
45,951,078
Trailing EPS
$-2.56
Book Value
$7.54
ROE
-34.6%
ROA
-22.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 8,995,000 | -92,780,000 | -80,605,000 | 294,889,000 | 22,838,000 | 272,051,000 | -81,627,000 |
| Dec 2024 | 0 | -78,194,000 | -71,109,000 | 358,234,000 | 35,107,000 | 323,127,000 | -51,522,000 |
| Dec 2023 | 0 | -48,400,000 | -63,854,000 | 25,924,000 | 199,320,000 | -173,396,000 | -37,362,000 |
| Dec 2022 | 0 | -39,969,000 | -39,722,000 | 28,429,000 | 140,988,000 | -112,559,000 | -36,181,000 |
TTM Snapshot
Revenues TTM
$10,355,000
NetIncome TTM
$-94,464,000
OpCashFlow TTM
—
Assets (Latest)
$396,929,000
Forward EPS
$-2.50
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $4.77 · call volume: 14 · put volume: 101
Expected Move to 2027-01-15:
±$1.45
(30.40%) —
implied range
$3.32 –
$6.22
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FTH | Faeth Therapeutics, Inc. | $233.63M | $9.04 | — |
| RCKT | ROCKET PHARMACEUTICALS, INC. | $235.60M | $2.11 | — |
| VNDA | Vanda Pharmaceuticals Inc. | $230.39M | $3.81 | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $229.72M | $7.97 | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $242.22M | $6.39 | — |
News headlines (Yahoo Finance, 1h cache)
BioAge Labs to Present at Upcoming Investor Conferences
2026-11-11 13:00 · Yahoo
BioAge Labs, Inc. (BIOA) Reports Q3 Loss, Misses Revenue Estimates
2026-11-05 21:45 · Yahoo
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-05 21:30 · Yahoo
Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline
2026-10-29 13:00 · Yahoo
Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target
2026-10-14 12:00 · Yahoo
BioAge Labs' Lead Drug Faces Uncertain Path as Data Looms, UBS Says
2026-10-12 17:02 · Yahoo
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
2026-08-06 00:35 · Yahoo
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-05 20:50 · Yahoo
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
2026-07-31 21:56 · Yahoo
BioArctic collaborator Novartis terminates agreement
2026-11-02 21:36 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.